U.S. Drug Enforcement Administration

Editor’s note: this article has been updated to reflect the views of the NCR more accurately. The U.S. Drug Enforcement Administration (DEA) has scheduled a hearing on Dec. 2, 2024, to discuss the proposed reclassification of cannabis as a Schedule III substance under the Controlled...

The Georgia Access to Medical Cannabis Commission (GMCC) recently convened a special meeting to discuss the ramifications of warning letters received from the U.S. Drug Enforcement Administration (DEA). These letters, directed at pharmacies involved in the state's medical marijuana program...

In a compelling move for cannabis reform, a coalition of military veterans organizations is asking President Biden to hasten the ongoing administrative review on marijuana scheduling. These groups, including prominent entities like Iraq and Afghanistan Veterans of America, have extended their...

Bright Green Corporation (NASDAQ: BGXX) has disclosed its financial results for the third quarter ending September 30, 2023. Under the leadership of executive chairman Terry Rafih, the company holds a position as one of the entities selected by the U.S. government to legally engage in the...

Cybin And Small Pharma Shareholders Green Light Acquisition Resolution Clinical-stage psychedelics biotechs Canada-based Cybin Inc. (NYSE: CYBN) and UK-based Small Pharma Inc. (OTCMKTS: DMTTF) held their respective annual general and special shareholders meetings on October 12. They announced that...

In a pivotal moment for the American cannabis sector, the U.S. Department of Health and Human Services (HHS) has proposed a reclassification of cannabis to the DEA. This could shift cannabis from its current Schedule I status, bringing potential upheaval in the perception and market dynamics of the...

"This is a big moment for us," says George Archos, CEO of Verano Holdings Corp (CSE: VRNO)(OTCQX: VRNOF), in light of the recent announcement where the Department of Health and Human Services (HHS) recommended the Drug Enforcement Administration (DEA) to reclassify cannabis from a...

Legislation Milestone: The Cannabis Rescheduling Debate Might Impact Brands The shifting perception of cannabis in the United States is witnessing a significant turning point. Once stigmatized as a Schedule I drug, might be on the verge of being reclassified to a potentially more accepted Schedule...

The U.S. cannabis landscape is in a dynamic state of change, with policy shifts and legislative updates shaping the industry's future.  Analysis Projects That Ohio Could Generate Up to $403.6 Million Annually From Legal Marijuana Sales A recent analysis by Ohio State...

The U.S. Department of Health and Human Services (HHS) is working to complete an administrative review of cannabis scheduling and aims to present President Joe Biden with a federal cannabis scheduling decision "this year," according to the head of the HHS Secretary Xavier Becerra,...

The future of ketamine telehealth clinics, the number of which grew during the Covid-19 pandemic, is uncertain due to new rules from the Drug Enforcement Administration (DEA). The rules, which aim to undo controlled substances prescribed via telehealth, have received over 21,000 public comments,...

The U.S. Drug Enforcement Administration (DEA) announced Monday that delta-9-THCO and delta-8-THCO do not occur naturally in the cannabis plant and can only be obtained synthetically. Therefore, they do not fall under the definition of "hemp,” according to a DEA letter made available to...

The Drug Enforcement Administration (DEA) has been sued over a failure to respond in due time to requests for psychedelics and cannabis records, reported Marijuana Moment. This new suit centers on the DEA’s alleged “unlawful policy of delaying responses to Freedom of...

A group of terminally ill patients seeking psilocybin therapy will likely take the Drug Enforcement Administration (DEA) to federal court once again over the agency’s denial to grant access to the treatment under Right To Try (RTT) laws, The Microdose reported.  The Right...

In a document published in the Federal Register, the Drug Enforcement Administration (DEA) announced it will hold a hearing on August 22, 2022, on its controversial proposal to place five psychedelic compounds in Schedule I.  The first plan to schedule the five tryptamines - 4-OH-DiPT, 5-...